Table 2.
Baseline Demographic and Disease Characteristics of Participants According to Age: Efficacy Population
| Characteristic | <75 | ≥75 | ||||
|---|---|---|---|---|---|---|
| Placebo, n = 1,204 | Canagliflozin 100 mg, n = 1,380 | Canagliflozin 300 mg, n = 1,391 | Placebo, n = 52 | Canagliflozin 100 mg, n = 61 | Canagliflozin 300 mg, n = 70 | |
| Sex, n (%) | ||||||
| Male | 704 (58) | 773 (56) | 760 (55) | 36 (69) | 38 (62) | 50 (71) |
| Female | 500 (42) | 607 (44) | 631 (45) | 16 (31) | 23 (38) | 20 (29) |
| Age, mean ± SD | 58.6 ± 8.8 | 57.9 ± 9.2 | 58.2 ± 8.9 | 76.8 ± 1.8 | 77.0 ± 1.7 | 77.1 ± 2.4 |
| Race, n (%) | ||||||
| White | 894 (74) | 1,015 (74) | 1,037 (75) | 49 (94) | 51 (84) | 62 (89) |
| Black | 42 (3) | 53 (4) | 66 (5) | 2 (4) | 1 (2) | 1 (1) |
| Asian | 174 (14) | 182 (13) | 181 (13) | 0 | 2 (3) | 5 (7) |
| Othera | 94 (8) | 130 (9) | 107 (8) | 1 (2) | 7 (11) | 2 (3) |
| Glycosylated hemoglobin, %, mean ± SD | 8.2 ± 0.9 | 8.1 ± 0.9 | 8.1 ± 1.0 | 8.0 ± 0.9 | 8.1 ± 0.9 | 7.9 ± 0.7 |
| Fasting plasma glucose, mg/dL, mean ± SD | 168.3 ± 44.5 | 170.6 ± 44.2 | 170.3 ± 47.2 | 172.4 ± 48.6 | 161.2 ± 39.9 | 163.5 ± 44.1 |
| Estimated glomerular filtration rate, mL/min per 1.73 m2, mean ± SD | 81.3 ± 20.6 | 84.1 ± 19.6 | 83.0 ± 20.1 | 66.2 ± 16.9 | 63.9 ± 15.8 | 65.0 ± 16.0 |
| Body mass index, kg/m2, mean ± SD | 32.8 ± 6.5 | 32.9 ± 6.5 | 32.7 ± 6.4 | 31.1 ± 5.0 | 29.7 ± 4.6 | 31.0 ± 5.0 |
| Duration of type 2 diabetes mellitus, years, mean ± SD | 11.3 ± 8.0 | 10.8 ± 7.8 | 10.8 ± 7.8 | 19.1 ± 10.5 | 17.9 ± 8.9 | 18.0 ± 8.5 |
Percentages may not total 100% because of rounding.
a
American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, not reported, other, unknown.
SD = standard deviation.